vs

Side-by-side financial comparison of Digimarc CORP (DMRC) and AVITA Medical, Inc. (RCEL). Click either name above to swap in a different company.

AVITA Medical, Inc. is the larger business by last-quarter revenue ($17.6M vs $8.9M, roughly 2.0× Digimarc CORP). Digimarc CORP runs the higher net margin — -47.2% vs -66.0%, a 18.7% gap on every dollar of revenue. On growth, Digimarc CORP posted the faster year-over-year revenue change (2.9% vs -4.3%). Digimarc CORP produced more free cash flow last quarter ($895.0K vs $-6.1M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs -5.3%).

Digimarc Corporation is a provider of enterprise software and services. The company's software, which includes digital identifiers, is designed to address counterfeiting, product authenticity, recycling accuracy, and supply chain traceability. Digimarc products are created for multiple industries such as apparel, consumer packaged goods, health and beauty, and automotive.

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

DMRC vs RCEL — Head-to-Head

Bigger by revenue
RCEL
RCEL
2.0× larger
RCEL
$17.6M
$8.9M
DMRC
Growing faster (revenue YoY)
DMRC
DMRC
+7.2% gap
DMRC
2.9%
-4.3%
RCEL
Higher net margin
DMRC
DMRC
18.7% more per $
DMRC
-47.2%
-66.0%
RCEL
More free cash flow
DMRC
DMRC
$7.0M more FCF
DMRC
$895.0K
$-6.1M
RCEL
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
-5.3%
DMRC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DMRC
DMRC
RCEL
RCEL
Revenue
$8.9M
$17.6M
Net Profit
$-4.2M
$-11.6M
Gross Margin
63.5%
81.2%
Operating Margin
-48.2%
-59.1%
Net Margin
-47.2%
-66.0%
Revenue YoY
2.9%
-4.3%
Net Profit YoY
51.4%
-0.3%
EPS (diluted)
$-0.18
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DMRC
DMRC
RCEL
RCEL
Q4 25
$8.9M
$17.6M
Q3 25
$7.6M
$17.1M
Q2 25
$8.0M
$18.4M
Q1 25
$9.4M
$18.5M
Q4 24
$8.7M
$18.4M
Q3 24
$9.4M
$19.5M
Q2 24
$10.4M
$15.2M
Q1 24
$9.9M
$11.1M
Net Profit
DMRC
DMRC
RCEL
RCEL
Q4 25
$-4.2M
$-11.6M
Q3 25
$-8.2M
$-13.2M
Q2 25
$-8.2M
$-9.9M
Q1 25
$-11.7M
$-13.9M
Q4 24
$-8.6M
$-11.6M
Q3 24
$-10.8M
$-16.2M
Q2 24
$-9.3M
$-15.4M
Q1 24
$-10.3M
$-18.7M
Gross Margin
DMRC
DMRC
RCEL
RCEL
Q4 25
63.5%
81.2%
Q3 25
58.3%
81.3%
Q2 25
58.8%
81.2%
Q1 25
65.0%
84.7%
Q4 24
60.8%
87.6%
Q3 24
62.4%
83.7%
Q2 24
66.1%
86.1%
Q1 24
62.5%
86.4%
Operating Margin
DMRC
DMRC
RCEL
RCEL
Q4 25
-48.2%
-59.1%
Q3 25
-109.7%
-53.6%
Q2 25
-105.2%
-60.5%
Q1 25
-128.9%
-63.9%
Q4 24
-105.1%
-54.1%
Q3 24
-120.4%
-70.6%
Q2 24
-96.2%
-102.8%
Q1 24
-109.2%
-155.0%
Net Margin
DMRC
DMRC
RCEL
RCEL
Q4 25
-47.2%
-66.0%
Q3 25
-106.9%
-77.3%
Q2 25
-102.6%
-53.9%
Q1 25
-125.2%
-74.9%
Q4 24
-99.9%
-63.0%
Q3 24
-113.9%
-82.9%
Q2 24
-89.3%
-101.3%
Q1 24
-104.0%
-168.0%
EPS (diluted)
DMRC
DMRC
RCEL
RCEL
Q4 25
$-0.18
$-0.37
Q3 25
$-0.38
$-0.46
Q2 25
$-0.38
$-0.38
Q1 25
$-0.55
$-0.53
Q4 24
$-0.40
$-0.44
Q3 24
$-0.50
$-0.62
Q2 24
$-0.43
$-0.60
Q1 24
$-0.50
$-0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DMRC
DMRC
RCEL
RCEL
Cash + ST InvestmentsLiquidity on hand
$12.9M
$18.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$40.2M
$-16.6M
Total Assets
$53.0M
$56.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DMRC
DMRC
RCEL
RCEL
Q4 25
$12.9M
$18.2M
Q3 25
$12.6M
$23.3M
Q2 25
$16.1M
$15.7M
Q1 25
$21.6M
$25.8M
Q4 24
$28.7M
$35.9M
Q3 24
$33.7M
$44.4M
Q2 24
$41.5M
$54.1M
Q1 24
$48.9M
$68.2M
Stockholders' Equity
DMRC
DMRC
RCEL
RCEL
Q4 25
$40.2M
$-16.6M
Q3 25
$41.4M
$-6.7M
Q2 25
$46.5M
$-12.9M
Q1 25
$50.0M
$-4.6M
Q4 24
$61.4M
$4.5M
Q3 24
$70.2M
$12.2M
Q2 24
$77.2M
$23.9M
Q1 24
$84.5M
$32.6M
Total Assets
DMRC
DMRC
RCEL
RCEL
Q4 25
$53.0M
$56.4M
Q3 25
$55.4M
$63.7M
Q2 25
$60.7M
$58.1M
Q1 25
$66.5M
$69.6M
Q4 24
$75.8M
$79.7M
Q3 24
$85.0M
$81.1M
Q2 24
$93.4M
$87.8M
Q1 24
$99.7M
$97.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DMRC
DMRC
RCEL
RCEL
Operating Cash FlowLast quarter
$991.0K
$-5.4M
Free Cash FlowOCF − Capex
$895.0K
$-6.1M
FCF MarginFCF / Revenue
10.0%
-34.7%
Capex IntensityCapex / Revenue
1.1%
3.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-12.3M
$-33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DMRC
DMRC
RCEL
RCEL
Q4 25
$991.0K
$-5.4M
Q3 25
$-2.6M
$-5.2M
Q2 25
$-4.7M
$-10.2M
Q1 25
$-5.5M
$-10.3M
Q4 24
$-4.2M
$-8.1M
Q3 24
$-7.1M
$-7.2M
Q2 24
$-6.8M
$-12.8M
Q1 24
$-8.4M
$-20.9M
Free Cash Flow
DMRC
DMRC
RCEL
RCEL
Q4 25
$895.0K
$-6.1M
Q3 25
$-2.8M
$-6.2M
Q2 25
$-4.9M
$-10.8M
Q1 25
$-5.5M
$-10.5M
Q4 24
$-4.2M
$-9.7M
Q3 24
$-7.2M
$-11.0M
Q2 24
$-6.9M
$-15.4M
Q1 24
$-8.5M
$-22.0M
FCF Margin
DMRC
DMRC
RCEL
RCEL
Q4 25
10.0%
-34.7%
Q3 25
-36.9%
-36.1%
Q2 25
-61.0%
-58.4%
Q1 25
-59.1%
-56.9%
Q4 24
-49.1%
-52.7%
Q3 24
-75.7%
-56.1%
Q2 24
-66.1%
-101.6%
Q1 24
-85.8%
-198.2%
Capex Intensity
DMRC
DMRC
RCEL
RCEL
Q4 25
1.1%
3.8%
Q3 25
2.9%
5.5%
Q2 25
2.5%
2.8%
Q1 25
0.6%
1.2%
Q4 24
0.2%
8.8%
Q3 24
0.7%
19.2%
Q2 24
0.3%
17.5%
Q1 24
1.1%
10.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DMRC
DMRC

Subscription$5.3M60%
The Government$3.6M41%

RCEL
RCEL

Segment breakdown not available.

Related Comparisons